Why Is Early EPI Detection Becoming More Important for Pancreatic Care?
Exocrine pancreatic insufficiency (EPI) is a condition in which the pancreas cannot produce enough digestive enzymes to break down food properly. This can affect nutrient absorption and lead to symptoms such as diarrhea, weight loss, abdominal discomfort and nutritional deficiencies.
Although EPI is commonly associated with chronic pancreatitis and cystic fibrosis, it can also develop following pancreatic surgery, pancreatic cancer and in some patients with diabetes. Many affected patients remain undiagnosed because these symptoms can resemble other digestive disorders.
This creates an important need for accessible and reliable diagnostic testing. The global exocrine pancreatic insufficiency diagnostics market is estimated at USD 459.67 million in 2026, compared with USD 430 million in 2025. It is projected to reach USD 838 million by 2035, growing at a CAGR of 6.90%.
Download PDF Sample: https://www.towardshealthcare.com/download-sample/7209
Market Size and Growth Outlook
| Market Indicator | Value |
|---|---|
| Market Size (2025) | USD 430.00 Million |
| Market Size (2026) | USD 459.67 Million |
| Projected Value (2035) | USD 838.00 Million |
| CAGR (2026–2035) | 6.90% |
The growth is closely connected to increasing awareness of pancreatic disorders, improved diagnostic infrastructure and the need for earlier identification of digestive complications. Hospitals and diagnostic laboratories are also expanding their testing capabilities to support patients with underlying pancreatic conditions.
Why Are Diagnostic Tests Becoming More Important?
Fecal elastase-1 testing remains the most widely used initial diagnostic approach for EPI. It measures pancreatic elastase in a stool sample and offers a relatively simple, non-invasive way to assess pancreatic exocrine function.
According to Towards Healthcare estimates, fecal elastase-1 tests accounted for 52% of the total market in 2025. Their affordability, availability and ease of sample collection support their leading position.
Other methods serve different clinical purposes. Fecal fat testing evaluates fat malabsorption, while breath tests assess digestive function. Secretin function tests provide a more direct assessment of pancreatic secretion, and imaging techniques help identify structural abnormalities.
| Diagnostic Method | Main Purpose | Clinical Advantage |
|---|---|---|
| Fecal Elastase-1 | Measures pancreatic elastase in stool | Non-invasive and suitable for initial assessment |
| Fecal Fat Testing | Measures fat in stool | Identifies fat malabsorption |
| Breath Tests | Evaluates digestive function | Non-invasive assessment |
| Secretin Function Tests | Measures pancreatic secretion | Direct functional assessment |
| Imaging | Examines pancreatic structure | Identifies underlying abnormalities |
No single method is suitable for every patient. Test selection depends on symptoms, medical history and the suspected underlying condition.
Which Patient Groups Are Creating More Demand?
Chronic pancreatitis accounted for 32% of the market in 2025, making it the leading indication segment. Repeated pancreatic inflammation can gradually damage enzyme-producing cells, increasing the likelihood of digestive insufficiency.
Cystic fibrosis is another important patient group because pancreatic dysfunction is common among affected individuals. Patients undergoing pancreatic surgery or receiving treatment for pancreatic cancer may also require follow-up assessments to identify digestive complications.
Diabetes is gaining attention as another potential area for EPI screening. Greater awareness of pancreatic dysfunction among these patients could expand diagnostic testing beyond traditional gastroenterology settings.
Regional Opportunities and Healthcare Infrastructure
North America held the largest regional share at 40% in 2025, supported by established diagnostic laboratories, specialist gastroenterology services and cystic fibrosis care infrastructure. Europe followed with 32%, reflecting established pancreatic disease management and diagnostic capabilities.
Asia Pacific accounted for 20% of global revenue and is projected to grow at the fastest CAGR of 8.01% between 2026 and 2035. Increasing healthcare investment, rising pancreatitis cases and expanding diagnostic facilities are supporting regional demand.
| Region | 2025 Market Share | Growth Outlook |
|---|---|---|
| North America | 40% | Established demand |
| Europe | 32% | Stable diagnostic adoption |
| Asia Pacific | 20% | Fastest growth, 8.01% CAGR |
| Latin America | Not specified | Gradual expansion |
| Middle East & Africa | Not specified | Developing diagnostic access |
Companies Competing in EPI Diagnostics
Competition involves diagnostic kit manufacturers, laboratory service providers and specialized testing companies. ScheBo Biotech led the market with an estimated 16% share in 2025, supported by its pancreatic elastase ELISA and Quick test products.
Other important participants include R-Biopharm, DiaSorin, Labcorp, Quest Diagnostics and BIOHIT HealthCare. Companies such as BÜHLMANN Laboratories, Immundiagnostik, Kibion and ChiRhoClin serve specialized testing requirements.
The competitive landscape depends on test accuracy, laboratory integration, sample handling, product availability and pricing. Manufacturers that improve testing convenience while maintaining clinical reliability can strengthen their position.
What Opportunities Can Diagnostic Companies Explore?
One important opportunity lies in improving EPI screening among patients with diabetes, chronic pancreatitis and those recovering from pancreatic surgery. Better awareness among clinicians could increase testing rates and support earlier diagnosis.
Another opportunity is the development of rapid fecal elastase tests and more accessible breath-based diagnostic solutions. These technologies could help gastroenterology clinics and diagnostic laboratories expand testing beyond large hospitals.
Asia Pacific also presents opportunities for companies seeking new distribution partnerships and laboratory collaborations. However, affordability, clinical awareness and access to specialized testing remain important considerations.
Conclusion
The EPI diagnostics industry is moving beyond traditional testing practices as healthcare providers pay greater attention to undiagnosed pancreatic dysfunction. Fecal elastase-1 testing currently leads demand, while breath tests, specialized functional assessments and imaging support a broader diagnostic approach.
For diagnostic manufacturers, laboratories and healthcare investors, the opportunity lies in improving test accessibility, supporting clinical awareness and identifying underserved patient populations. Companies that understand regional testing requirements and changing clinical needs will be better positioned to compete in this growing industry.
About Us
Healthcare WebWire is a part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.
Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]
Europe Region - +44 778 256 0738
North America Region - +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com